Business Description
Newbury Pharmaceuticals AB
ISIN : SE0015244884
Total Employee Number:
7Compare
Compare
Traded in other countries / regions
NEWBRY.SwedenP52.Germany IPO Date
2022-02-04Description
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.41 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 0.45 | |||||
Beneish M-Score | -3.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 54.3 | |||||
3-Year EBITDA Growth Rate | 8.5 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | 38 | |||||
3-Year Book Growth Rate | -26.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.29 | |||||
9-Day RSI | 44.58 | |||||
14-Day RSI | 47.27 | |||||
3-1 Month Momentum % | 119.7 | |||||
6-1 Month Momentum % | 152.17 | |||||
12-1 Month Momentum % | 11.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.12 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 136.08 | |||||
Days Sales Outstanding | 78.57 | |||||
Days Payable | 110.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 26.47 | |||||
Operating Margin % | -81.03 | |||||
Net Margin % | -86.91 | |||||
EBITDA Margin % | -63.38 | |||||
FCF Margin % | -46.01 | |||||
OCF Margin % | -46.01 | |||||
ROE % | -68.4 | |||||
ROA % | -34.59 | |||||
ROIC % | -37.1 | |||||
3-Year ROIIC % | -976.16 | |||||
ROCE % | -55.95 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.21 | |||||
PB Ratio | 2.41 | |||||
Price-to-Tangible-Book | 62 | |||||
EV-to-EBIT | -2.46 | |||||
EV-to-EBITDA | -3.14 | |||||
EV-to-Revenue | 1.99 | |||||
EV-to-FCF | -4.86 | |||||
Price-to-GF-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 62 | |||||
Earnings Yield (Greenblatt) % | -40.61 | |||||
FCF Yield % | -20.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Newbury Pharmaceuticals AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 32.775 | ||
| EPS (TTM) (kr) | -0.987 | ||
| Beta | -0.0421 | ||
| 3-Year Sharpe Ratio | 0.07 | ||
| 3-Year Sortino Ratio | 0.13 | ||
| Volatility % | 84.79 | ||
| 14-Day RSI | 47.27 | ||
| 14-Day ATR (kr) | 0.276634 | ||
| 20-Day SMA (kr) | 2.652 | ||
| 12-1 Month Momentum % | 11.97 | ||
| 52-Week Range (kr) | 0.76 - 7.88 | ||
| Shares Outstanding (Mil) | 30.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Newbury Pharmaceuticals AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Newbury Pharmaceuticals AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2027-01-20 | In 145 days | ||
| General meeting for 2026 | 2027-01-20 | In 145 days | ||
| Annual report for 2026 | 2026-12-16 | In 110 days | ||
| Fourth quarter earnings results for 2026 | 2026-10-28 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-07-08 | 2.34 (+17.00%) | ||
| Second quarter earnings results for 2026 | 2026-04-15 | 1.18 (+2.16%) | ||
| First quarter earnings results for 2026 | 2026-01-14 | 1.33 (+8.61%) | ||
| General meeting for 2025 | 2026-01-14 | 1.33 (+8.61%) | ||
| Annual report for 2025 | 2025-12-10 | 1.46 (+3.55%) | ||
| Fourth quarter earnings results for 2025 | 2025-10-29 | 2.46 (+2.93%) |
Show
Entries
Newbury Pharmaceuticals AB Frequently Asked Questions
What is Newbury Pharmaceuticals AB(OSTO:NEWBRY)'s stock price today?
The current price of OSTO:NEWBRY is kr2.48. The 52 week high of OSTO:NEWBRY is kr7.88 and 52 week low is kr0.76.
When is next earnings date of Newbury Pharmaceuticals AB(OSTO:NEWBRY)?
The next earnings date of Newbury Pharmaceuticals AB(OSTO:NEWBRY) is 2026-10-28.
Does Newbury Pharmaceuticals AB(OSTO:NEWBRY) pay dividends? If so, how much?
Newbury Pharmaceuticals AB(OSTO:NEWBRY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Newbury Pharmaceuticals AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers